List of All Previous Posts:

• Merrimack Pharmaceuticals Reports First Quarter 2012 Financial Results
• Merrimack Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
• Merrimack Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
• Phase 1 Data on MM-398 will be Presented at the ASCO 2012 Gastrointestinal Cancers Symposium
• Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
• Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
• Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
• Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
• Multiple Programs from Merrimack Pharmaceuticals’ Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
• Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
• Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-302 in HER2 Positive Breast Cancer Patients
• FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals’ MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
• Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
• Multiple Programs from Merrimack Pharmaceuticals’ Pipeline to be Presented at the 2011 ASCO Annual Meeting
• Merrimack Pharmaceuticals Acquires European and Asian Rights to MM-398, nanoliposomal irinotecan
• Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
• Merrimack Pharmaceuticals Raises $77 Million in Private Financing
• Phase 1 Data on MM-121 Will Be Presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR)
• Merrimack to Present Pre-Clinical Data on MM-111 and MM-302 at the 102nd Annual Meeting of the American Association for Cancer Research (AACR)
• Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
• Michael Porter, Janet Woodcock, Peter Senge among speakers at inaugural Innovation in Healthcare Symposium
• Merrimack to Present Preclinical and Phase 1 Data at the 33rd Annual San Antonio Breast Cancer Symposium
• Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Combination Study of MM-121 and paclitaxel in Gynecologic and Breast Cancers
• Merrimack Pharmaceuticals Awarded $2.44 Million in Grants Under the Patient Protection and Affordable Care Program
• Merrimack Pharmaceuticals and sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 and exemestane in Breast Cancer
• Melissa Kemp, Ph.D. Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
• Merrimack Pharmaceuticals’ MM-111 Phase 1/2 Trial Design to be Presented at the 2010 ASCO Annual Meeting
• Co-Founder Gavin MacBeath, Ph.D. joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research
• Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 /2 Combination Study of MM-111 and Herceptin® in Patients with Advanced Her2 Positive Breast Cancer
• Merrimack to Present at BIO on the Development of MM-111, a Novel Bispecific ErbB2/ErbB3 Antibody with Potent Anti-Tumor Activity
• Merrimack to Present Pre-clinical Data on MM-121 and MM-111 at 101st Annual Meeting of the American Association for Cancer Research (AACR)
• Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
• Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Combination Study of MM-121 and Tarceva® in Patients with Non-Small Cell Lung Cancer
• Merrimack Receives $1.5 Million Tax Incentive from Governor Patrick and the Massachusetts Life Sciences Center
• Sanofi-aventis and Merrimack Pharmaceuticals enter into a Worldwide Collaboration and Licensing Agreement on MM-121, an anti-ErbB3 monoclonal antibody
• Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
• Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Study of MM-111, a bispecific antibody to ErbB2/3
• ‘Science Signaling’ to Publish Paper on Therapeutically Targeting Erb3 to Treat Overexpressed or Mutated Oncogenes
• Merrimack Pharmaceuticals to Present Pre-Clinical Data on MM-121 and MM-111 at the Annual Meeting of the American Association for Cancer Research